Terry Wilcox

3 days ago | californiaglobe.com | Terry Wilcox

California lawmakers are about to hand hospitals and pharmacies a massive windfall and stick patients with the bill. Assembly Bill 1460 by Assemblyman Chris Rogers (D-Santa Rosa), which passed out of the State Assembly in May, would expand the 340B Drug Pricing Program, a federal initiative that has become one of America’s most profitable healthcare schemes for hospitals and pharmacies.

3 weeks ago | washingtontimes.com | Terry Wilcox

OPINION: Long-term health care awareness and conversation are rising in America, but most have not heard of the Program of All-Inclusive Care for the Elderly. For the nation’s most vulnerable seniors, particularly in Ohio, where officials are trying to get the program off the ground, PACE could be life-changing if properly implemented and managed. PACE is designed to deliver wraparound medical and social services to low-income seniors who qualify for nursing home care.

2 months ago | latrobebulletinnews.com | Terry Wilcox

Thirty million Americans live with a rare disease, with half diagnosed being children. Despite the serious challenges facing this particularly vulnerable patient group, 9% of rare diseases — of which there are more than 10,000 — still lack an FDA-approved treatment. There is a clear and pressing need to accelerate investment in and the production of innovative treatments and cures for rare disease patients.

2 months ago | dcjournal.com | Terry Wilcox

Thirty million Americans live with a rare disease, with half diagnosed being children. Despite the serious challenges facing this particularly vulnerable patient group, 95 percent of rare diseases — of which there are more than 10,000 — still lack an FDA-approved treatment. There is a clear and pressing need to accelerate investment in and the production of innovative treatments and cures for rare disease patients.

Jul 25, 2024 | medcitynews.com | Terry Wilcox

With over 7,000 rare diseases affecting more than 30 million people in the United States, the tight-knit community of rare disease patients, providers, researchers, and peer groups is incredibly supportive, but the regulatory environment has been much less so. It has long been divided by disease-specific research and treatment silos, and most clinical research is disease-specific without overlap or input from other experts in related fields.